Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 45

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 45
---
,126 for Dr. Pastagia and $7,317 for Mr. Rychlik, and severance payments of $475,072 for Dr. Pastagia and $75,400 for Mr. Rychlik. Base Salary The base salaries of the named executive officers in 2024, as applicable, were generally determined and approved by the Board of Directors, based on the recommendation of the Compensation Committee. • Dr. Birx’s annual base salary was $525,000 through January 7, 2024, and increased to $546,000 effective January 8, 2024 through December 31, 2024. • Dr. Kyme’s annual base salary was $300,880 through January 7, 2024, $312,915 from January 8 to February 11, 2024, $342,915 from February 12 to May 31, 2024, and $400,000 from June 1 to December 31, 2024. • Mr. House’s annual base salary from his start date on August 16, 2024 through December 31, 2024 was $350,000. • Dr. Pastagia’s annual base salary was $456,800 through January 7, 2024, and increased to $475,072 effective January 8, 2024 through her departure on November 1, 2024. • Mr. Rychlik’s annual base salary was $290,000 through January 7, 2024, and increased to $301,600 effective January 8, 2024 through his departure on September 30, 2024. Equity-Based Awards Our equity-based incentive awards are designed to align the interests of our employees and consultants, including the named executive officers, with those of our shareholders. Our board of directors or our Compensation Committee approve equity grants. Vesting of equity awards was generally tied to continuous service and serves as an additional retention measure. Our executives may have been awarded an initial new hire grant upon commencement of service and have received additional grants, as the board of directors or Compensation Committee determined appropriate, in order to incentivize and/or reward such executives. In 2023 and 2024, we granted both nonqualified stock options and restricted stock units to our named executive officers under our equity incentive plans. The following information is being provided as required by Item 402(x) of Regulation S-K. The Company does not maintain a formal policy or guidelines relating to the